Medivant Healthcare

What Medivant Healthcare does

Medivant Healthcare is an FDA-registered 503B outsourcing facility that manufactures sterile injectable generic medications, primarily targeting products listed on the US FDA Drug Shortage List. Founded in 2015 and headquartered in Chandler, Arizona (legal entity Tailstorm Health Inc., incorporated in Arizona), the company operates two fully automated cGMP-compliant manufacturing facilities in Arizona that have been inspected by the US FDA with an Establishment Inspection Report (EIR) filed. It serves hospitals, retina clinics, and hospital outpatient pharmacies in the United States through direct B2B enterprise sales, with segment-specific customer registration flows for each buyer type. Leadership is anchored by CEO Viraj Gandhi, President Ramesh Vijayaraghavan, and an executive bench that includes VPs across institutional sales, quality, engineering, product innovation, and business technology.

The company's technical platform is built around fully automated manufacturing under ISO 5 and ISO 7 controlled environments. Core equipment includes a 240-liter automated compounding vessel, a filling machine capable of 1–30 ml vial formats at 100 vials per minute, a terminal sterilizer operating with a 10 log 6 overkill approach, an in-house Water for Injection (WFI) system on an SS316L orbital welded loop with 6 GMP output capacity, and DCSA-compliant inline serialization at 200 vials per minute. Single Dose Liquid Injectable Vials (1–10 ml) constitute the core product line at 40,000 vials/day, with a stated target of 50,000 vials/day. The prefilled syringe product — repackaged Avastin in Ompi Alba glass syringes — carries an independently verified 365-day Beyond-Use Date, positioned as the longest available in the market for ophthalmic and retina care. The company currently offers 10 products with a stated pipeline of approximately 300, and has delivered 10,000+ units cumulatively.

The go-to-market model is direct enterprise sales to licensed healthcare facilities, with pricing not publicly disclosed and likely negotiated per account. Distribution is restricted to US jurisdictions where the company is properly licensed, registered, or authorized. Medivant Healthcare is privately held with no external institutional investors, private equity affiliations, or parent company disclosed in the available materials. The company is registered as a 503B outsourcing facility under the Drug Quality and Security Act and operates under 21 CFR Part 820 quality system regulations. Beyond Arizona manufacturing operations in Chandler and North Phoenix, a Princeton, New Jersey office supports East Coast commercial activity.

Name

Medivant Healthcare

Legal name

Tailstorm Health Inc.

Website

https://medivanthealth.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Medivant Healthcare is an FDA-registered 503B outsourcing facility manufacturing sterile injectable generics on the US FDA Drug Shortage List, serving hospitals, retina clinics, and hospital outpatient pharmacies via direct B2B sales.

Ownership category

akta.pro rank

Headquarters

HQ city

Chandler

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Sterile Injectable Generic Manufacturing: Manufacturing and sale of sterile generic injectable medications (Single Dose Liquid Injectable vials) targeting medications on the US FDA Drug Shortage List. Production capacity of 40,000 vials daily.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Medivant Healthcare is a boutique, cGMP-compliant 503B outsourcing facility that manufactures sterile injectable generic medications, primarily Single Dose Liquid Injectable Vials (1–10 ml) and Pre-filled Syringes (repackaged Avastin for ophthalmic use). Production is targeted at drugs on the US FDA Drug Shortage List and is sold directly to hospitals, retina clinics, and hospital outpatient pharmacies through enterprise B2B sales.

Product overview

Medivant Healthcare operates as a unified pharmaceutical manufacturing platform offering sterile injectable generics and repackaging services. The core product portfolio consists of Single Dose Liquid Injectable Vials manufactured at their automated Chandler, Arizona facility, alongside Pre-filled Syringes featuring repackaged Avastin for ophthalmic care. Supporting services include custom pharmaceutical solutions, supply chain management, and consultation partnerships with healthcare providers. The company positions itself as addressing U.S. FDA Drug Shortage List medications through efficient cGMP manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• Single Dose Liquid Injectable Vials Sterile injectable generic medications manufactured as single-dose liquid vials (1–10 ml), produced in a fully automated cGMP-compliant facility in Chandler, Arizona at 40,000 vials per day (with a target of 50,000 vials per day). Sold to hospitals, retina clinics, and hospital outpatient pharmacies, with a focus on US FDA Drug Shortage List medications.
• Pre-filled Syringes (Repackaged Avastin) Repackaged Avastin (bevacizumab) in pre-filled Ompi Alba glass syringes for ophthalmic/retina use, with automated filling, superior dosing precision versus manual preparation, and an independently verified 365-day Beyond-Use Date — the longest available in the market. Sold to ophthalmology and retina clinics.
• Custom Pharmaceutical Solutions Tailored pharmaceutical solutions designed to meet unique needs of hospitals and healthcare providers, leveraging Medivant's automated cGMP manufacturing and 503B outsourcing capabilities.

Quantifiable outcome

• 40,000 vials/day production capacity with goal to reach 50,000
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature8 records

Scale indicators13 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• QuVa Pharma: QuVa Pharma is a 503B outsourcing facility producing sterile injectable compounds for hospitals, the closest direct peer to Medivant in the 503B outsourcing space. Both companies target hospital pharmacy customers with ready-to-administer sterile preparations.
• Leiters: Leiters is a 503B outsourcing compounder producing sterile injectable preparations, particularly repackaged Avastin for ophthalmic use. They directly compete with Medivant in the retina clinic prefilled syringe segment.
• Amphastar Pharmaceuticals: Amphastar is a specialty injectable pharmaceutical manufacturer with significant generic sterile injectable operations, including products competing in shortage categories. Comparable in business model focused on generic injectables.
• Hikma Pharmaceuticals: Hikma is a major generic sterile injectable manufacturer with substantial US hospital-facing operations, directly competing in the same generic injectable shortage categories as Medivant.

Broad incumbents

• Hospira (Pfizer): Hospira, owned by Pfizer, is the largest US supplier of sterile injectable generics. As a broad incumbent, they compete with Medivant across most shortage categories but with vastly greater scale and broader portfolio.
• Fresenius Kabi: Fresenius Kabi is a leading global manufacturer of sterile injectable generics and IV therapies with a broad hospital-facing portfolio. They are a major incumbent competitor to Medivant in shortage products.
• Endo Pharmaceuticals: Endo's Par Pharmaceutical sterile injectable business is a broad incumbent in generic injectables, including shortage products. They compete with Medivant across hospital-facing injectables.
• Aurobindo Pharma: Aurobindo is a major generic pharmaceutical manufacturer with growing sterile injectable operations in the US market, competing with Medivant in generic injectable categories.
• Apotex: Apotex is a large Canadian generic pharmaceutical manufacturer with a US injectable portfolio that competes in similar shortage categories as Medivant through its hospital channel.

Emerging players

• Pharmaceutics International Inc (PII): PII is a CDMO focused on sterile injectable fill-finish services with 503B capabilities, providing comparable contract manufacturing and outsourcing services to healthcare providers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medivant-health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medivant Healthcare